GAIA BioMedicine

GAIA BioMedicine, Inc., founded in 2015 by Professor Yoshikazu Yonemitsu (Kyushu University Graduate School), is a spin-off company from Kyushu University. Currently, as a clinical-stage, technology-driven biopharmaceutical company, Gaia is advancing a solid cancer cell therapy program based on Gaia-102 (NK-like cells).